Neuroendocrine differentiation in tumors of the upper and lower urinary tracts, prostate, and testis is rare. The current review surveys the most significant pathologic and clinical features of primary neuroendocrine lesions at these sites, with emphasis on the cell types from which they derive. As many tumors in this spectrum often bear strong morphologic resemblance to similar neoplasms in other organs, the importance of considering secondary involvement of the genitourinary tract cannot be overstated.
N euroendocrine (NE) lesions of the genitourinary (GU) organs are a diverse group of neoplasms with varying incidence, clinicopathologic presentation, and outcome. Three major theories regarding the origins of these tumors include (1) derivation from amine precursor and decarboxylation (APUD) cells of the diffuse NE system-such as those identified in the normal urothelial tract and prostate, which, like their counterparts in the gastrointestinal tract, are typically situated against the basement membrane of an epithelial surface and may increase in number in reactive or metaplastic settings; (2) derivation from a multipotent stem cell-a concept especially relevant to NE tumors arising in conjunction with or as a component of epithelial or germ cell malignancy; (3) derivation from non-APUD cell NE structures-encompassing lesions such as bladder paraganglioma (PG), and its rare counterparts in other organs. Within this review, the origins of each entity are discussed in relationship to relevant epidemiologic, clinicopathologic, immunohistochemical, and prognostic data. Additionally, differential diagnostic considerations of major clinical import have been highlighted.
NEUROENDOCRINE LESIONS OF UROTHELIUM

High-grade Neuroendocrine Carcinoma
Previous reports of high-grade neuroendocrine carcinoma (NEC), primarily involve small cell carcinoma (SmCC) of bladder, which accounts for 0.5% to 1% of primary bladder malignancies. [1] [2] [3] SmCC is comparable to usual high-grade urothelial carcinoma (UC) with regard to median age in the seventh decade, sex (M:F ratio-2:1 to 5:1) 4-5 and clinical presentation with hematuria (>75%). 1 Unlike its counterpart in the lung, 6 however, bladder SmCC is uncommonly associated with paraneoplastic syndromes, with rare reports of sensory neuropathy and hypercalcemia. 5 Grossly, SmCC measure up to 13 cm, 7 may grow as sessile, nodular, polypoid, ulcerated, and/or infiltrative lesions, 8 and may be localized to any region of the bladder, including diverticulae. 2, 9, 10 Microscopically, high-grade NEC represents a spectrum of findings. ''Pure'' SmCC cases are infrequent, with approximately 50% revealing an admixture of other carcinomatous elements, including UC not otherwise specified (Fig. 1A) , adenocarcinoma ( Fig. 1B) , squamous cell carcinoma, and/or sarcomatoid features. 9, 11 The coexistence of these epithelial components, and identification of overlying papillary or flat non-invasive UC (Fig. 1C ), strongly suggests that the high-grade NE phenotype reflects divergent differentiation of multipotent malignant urothelial cells. 1, 12 Furthermore, even within the NEC component, tumors exhibit a range of morphology, from ''classic'' SmCC features, as seen in the lung, that is, diffuse sheets of round blue hyperchromatic cells exhibiting nuclear molding, granular chromatin, inconspicuous nucleoli, scant cytoplasm, and frequent mitoses/apoptotic debris to lesions with a large cell neuroendocrine (LCNEC) phenotype, including better-defined organoid, palisaded, or trabecular architecture and large cells with abundant cytoplasm and macronucleoli 13 (Fig. 1D ). In areas, the latter may convey a ''carcinoidlike'' architecture at low power, albeit with cytologic features better associated with high-grade NEC (Fig. 1E ). Focal to diffuse areas of geographic necrosis, rare tumor giant cells, Azzopardi phenomenon, and overall lack of a desmoplastic response may be seen across the gamut of high-grade NEC. 9 A key differential diagnostic consideration is direct extension or metastasis from nonurothelial NEC. In addition to morphologic overlap, the difficulty in distinguishing primary from secondary lesions is compounded by immunohistochemical and ultrastructural similarities, including cytoplasmic chromogranin and synaptophysin positivity, ''dotlike'' cytokeratin positivity, 4, 12 and sparse intracytoplasmic membrane-bound dense core granules. 9, 12 Although initially proposed as a specific marker for pulmonary SmCC, 14, 15 thyroid transcription factor-1 positivity has subsequently been demonstrated in 25% to 39% of bladder SmCC, 16, 17 limiting its utility in this differential diagnosis. 18 Given these similarities, metastatic high-grade NEC (eg, from lung) secondarily involving a urothelial-lined organ must be excluded on clinical and radiologic grounds, taking into account that solitary metastasis to a GU site would be highly improbable. Regarding direct extension of a high-grade NEC, approximately half of prostatic SmCC have an associated conventional adenocarcinoma component, making immunopositivity for prostate-specific antigen (PSA) or prostatic acid phosphatase (PAP) in better-differentiated areas a useful adjunct. On occasion, malignant lymphoma may widely invade the bladder wall and mimic SmCC. Although cytologic features will usually distinguish the two, an immunohistochemical panel of cytokeratin, CD45, CD20, CD3, and NE markers may be helpful in difficult cases. 8 Bladder SmCC typically presents with high clinical stage, with only rare documentation of nonmuscleinvasive disease. 1, 19 These tumors frequently display rapid growth and metastasis at the time of or shortly after diagnosis to lymph nodes (LNs), viscera, and vertebral bones. 1, 2, 4, 5, 9, 10, 20 Accordingly, available outcome data suggests a poor prognosis, correlating with advanced stage at presentation. 2 Parallel clinicopathologic features and outcomes have been reported for exceedingly rare cases of SmCC of the ureters and renal pelvis, as well as LCNEC of lower or upper tract. 3, 12, 13, [21] [22] [23] [24] With regard to treatment, most modern series have advocated regimens containing cisplatin-based chemotherapy 25 in addition to surgical resection 4, 26 or radiotherapy 2,27,28 as being beneficial. Given the propensity of high-grade NEC for early systemic disease, some have further advocated neoadjuvant therapy with pulmonary SmCC dosages and reported improved 5-year cancer-specific survival for these patients versus those receiving platinum-based therapy in the adjuvant setting. 19 At this time, however, the ideal timing and dosing of these treatments remains unknown due to the retrospective and/or limited nature of prior studies. 29 Similarly, the low frequency of urothelial high-grade NEC and its tendency to exhibit a range of morphologies have precluded clinically meaningful pathologic subclassification. Diagnostically, therefore, it is reasonable to recommend reporting these cases as high-grade UC with small cell/NE differentiation, while noting explicitly the extent of the NE component, as it may affect therapeutic options.
ADDITIONAL NEUROENDOCRINE LESIONS OF BLADDER
Bladder Paraganglioma
PGs of the bladder, also termed pheochromocytomas, represent <0.5% of all bladder tumors and 10% of extraadrenal PG. 30, 31 They occur in a 3:2 female to male predominance and in up to 3/4 of patients exhibit a classic clinical triad of sustained or paroxysmal hypertension, intermittent gross hematuria, and micturition ''attacks,'' the latter characterized by headache, palpitations, blurred vision, profuse sweating, tremulousness, and occasional syncope. 32, 33 Moreover, manipulation of tumor during cystoscopy or intraoperatively may elicit a hypertensive response.
Grossly, most of these well-circumscribed lesions measure <4 cm and are solitary and exophytic. 32 Microscopically, usual findings include nests (Zellballen) of polyhedral cells with amphophilic or basophilic cytoplasm and ovoid nuclei intertwined within a delicate vascular network ( Fig. 2 ). However, irregular growth, bizarre endocrine atypia, rare mitoses, dense fibrous septae, and focal ganglioneuromatous or neuroblastlike growth may also be seen. 31 Immunohistochemical staining reveals a pattern identical to that of adrenal pheochromocytomas, with chromogranin and synaptophysin positivity in chromaffin cells, S-100 protein positive sustentacular cells, and negativity for keratins. 34, 35 Similar to other extra-adrenal PG, vesical-based lesions are thought to arise by malignant transformation of paraganglia. 31, 32, [36] [37] [38] In an elegant autopsy study of over 400 patients, Honma 39 has demonstrated paraganglia at all levels of the wall, including within detrusor muscle, in >50% of patients. Although approximately 80% of patients in the few existing small series have shown at least ''muscle invasive disease,'' the origin of bladder PG within the bladder wall or surrounding soft tissue makes traditional staging difficult. 35, 40 Furthermore, although cytologic atypia, tumor size, muscle invasion, and lymphovascular invasion have been proposed as markers of malignancy, none has shown independent predictive value for outcome. Metastatic disease, as occurs in 10% to 15% of cases-primarily to iliohypogastric LN locally and lung systemicallyremains the determinant of malignancy in bladder PG. 34 Their capacity of PG to invade deeply, along with their Zellballen architecture necessitates distinction from nested patterns of UC, especially in small biopsies or those with thermal artifact. 35 While infiltrative nests of UC, often lacking desmoplasia, may mimic PG, the latter should not exhibit superficial urothelial disease, true cytologic atypia, or significant mitotic rates. Furthermore, other than focally, nested variants of UC lack the fine vasculature characteristic of PG. In difficult cases, immunopositivity for CK7, 20, and HMW cytokeratin, as seen in UC, will resolve the dilemma. 35 Benign para- ganglia, composed of small collections of clear to amphophilic cells, may occasionally cause diagnostic confusion with full-fledged PG in a small sample. 35 In this scenario, clinical symptoms and cystoscopic evidence of a mass, coupled with repeat biopsy documenting extent of disease, should clarify the issue.
Bladder Carcinoid
Less than 10 true primary bladder carcinoids have been documented, [41] [42] [43] [44] [45] [46] presenting as small, 0.3 to 1.2 cm, polypoid masses at the bladder neck/trigone in patients with hematuria. Martignoni and Eble 45 have assessed an additional group of reported cases, which upon review of descriptions and illustrations, better represented SmCC or PG. Tumors demonstrate classic carcinoid architectural patterns including glandular, acinar, cribriform, or trabecular arrangements of uniform cells with basally oriented eosinophilic cytoplasm. 45 One unusual bladder carcinoid was identified subjacent to an otherwise typical inverted urothelial papilloma. 44 When considering a diagnosis of primary carcinoid tumor anywhere in the GU tract, it is essential to thoroughly exclude a metastatic lesion from more common sites such as lung or gastrointestinal tract. In the bladder specifically, pathologists must also bear in mind that urothelial high-grade NEC may also exhibit focal carcinoidlike or organoid growth. 9 Unlike SmCC of the urinary bladder, which may be considered divergent differentiation from UC, an association of bladder carcinoids and UC has not been observed. It is well known, however, that cells with NE features may be situated against the basement membrane of normal urothelium, as well as in reactive lesions such as von Brunn nests and cystitis cystica et glandularis. 47, 48 Indeed, 2 cases of primary bladder carcinoid have developed in a background of proliferative cystitis of the overlying urothelium, 43, 45 including 1 case with scattered argyrophil cell staining noted in this component. 43 A proposed origin of primary bladder carcinoid from innate or metaplastic mucosal urothelial NE cells is consistent with these findings. 
NEUROENDOCRINE LESIONS OF KIDNEY
Renal Carcinoid
Carcinoid tumor of the kidney is uncommonly encountered, with up to one-third of affected patients younger than 40 years. Similar to patients with renal cell carcinoma (RCC), those with carcinoid tumors at this site present with abdominal, back, or flank pain, accompanied by hematuria and fever. 49, 50 Twenty-five to thirty percent of renal carcinoids are incidentally detected 51 and diagnosis may be complicated with small lesions, as neither computed tomography nor magnetic resonance imaging reliably distinguishes these tumors from RCC. 52 Evidence of carcinoid syndrome with serotonin-related flushing, generalized edema, and diarrhea, and occasional elevation of urine 5-HIAA may occur in 10% to 15% of patients. 53 In its presence, somatostatin receptor scintigraphy with octreotide has a high sensitivity for renal carcinoid detection, including small, clinically silent lesions. 54 Grossly, 70% of these masses are solid, measuring between 1.5 and 30 cm, with the remainder partially or predominantly cystic. Histologically, polygonal tumor cells with indistinct cell borders, round regular nuclei, ''salt and pepper'' chromatin, and infrequent mitoses grow in trabecular and nested patterns (Figs. 3A, B) , set in a highly vascularized, yet thin fibroconnective tissue background. Glandular (Fig. 3C) , solid, or rosettelike growth and densely fibrotic/sclerotic stroma may also be observed. 53, 55 Ultrastructural studies demonstrate abundant neurosecretory granules and diffuse labeling for cytokeratin, chromogranin, and synaptophysin is typical. 49, 53 Interestingly, these tumors have demonstrated positivity for PAP, suggesting hindgut origin. 49, 50, 53, 56 As in other sites, metastasis from a remote carcinoid tumor must be excluded. Finally, approximately 15% of reported cases have been initially diagnosed as RCC or Wilms tumor, 54, 57 likely due to under-recognition of renal carcinoid, with uniformly negative WT-1 also ruling out the latter possibility. 58 Owing to the vacuous nature of the retroperitoneal space, these slow-growing neoplasms are usually diagnosed at a large size, with B75% being >4 cm. 52 A recent review of this entity found that nearly 45% of reported patients have pT3 disease (tumor invading perirenal or sinus/hilar fat or invading renal vein). Consequently, metastatic disease is seen in 50% to 60% of cases and is usually detected at initial evaluation. However, distant spread from primary renal carcinoids has been reported up to 7 years postnephrectomy, mandating long-term follow-up for these patients. 53, 59, 60 Metastatic lesions involve periaortic and perihilar LN, liver, and bone 52 and their presence may correlate with age >40 years, tumors >4 cm, pT3 tumors, and mitotic rates >1 per 10 HPF. Surprisingly, however, more than 90% of reported patients were without evidence of disease or alive with disease (median 34-mo follow-up), whereas 47% of patients with LN metastases at the time of resection showed no evidence of disease (mean 43 months follow-up). 51, 52, 59, 61 Hence, patients with renal carcinoids may experience a prolonged clinical course, even in the presence of widely metastatic disease.
Fascinating associations between primary renal carcinoid and horseshoe kidney (18% to 26%) or renal teratomas (B15% of patients) have been reported. 60, [62] [63] [64] [65] [66] These findings have led some to postulate that hyperplasia of interspersed NE cells within metaplastic or teratomatous epithelium in horseshoe kidneys or nests of misplaced progenitor cells developing into teratomatous intestinal or respiratory epithelia in renal teratoma (Fig. 3D ) may serve as a nidus for renal carcinoids. 65, 67 This view is supported by the common occurrence of renal carcinoids in the isthmus of horseshoe kidneys, a region formed by abnormal migration of posterior nephrogenic cells in utero. 65 However, nearly 65% of reported lesions have not occurred in these settings. Other suggestions, including reactive NE metaplasia of the pyelocaliceal system and NE differentiation of multipotent renal stem cells have been fielded, yet neither pyelonephritis/renal calculi nor areas of renal carcinoid coexistent with UC or RCC have been observed. 62, 65 Although the presence of intrinsic NE cells in normal kidney may be debated, rare NE cells have been observed in urothelium of the upper tract. 55, 68 It is plausible, therefore, that renal carcinoids bearing no relationship to congenital/acquired abnormalities arise directly from NE cells situated in the renal pelvic urothelium.
NEUROENDOCRINE LESIONS OF TESTIS
Testicular Carcinoid
Representing approximately 0.2% of all testicular neoplasms in a historical series from the Armed Forces Institute of Pathology, 69 primary testicular carcinoids are infrequent, with reported patients ranging from 10 to 83 years. 70 Not unlike germ cell tumors in general, testicular carcinoids typically present with a mass or testicular swelling, accompanied by pain and tenderness. 69 Clinical carcinoid syndrome may be seen in up to 10% of cases. 70 Grossly, these lesions are solid, yellow-tan wellcircumscribed nodules, measuring 0.5 to 11 cm. An accompanying cystic component may be observed when seen in conjunction with other teratomatous elements. 69 Microscopically, they share characteristic features, immunoprofile, and ultrastructural polymorphous neurosecretory granules with carcinoids at other sites (Fig. 4A ). [69] [70] [71] [72] Although most behave in an indolent manner, 10% to 15% metastasize, occasionally many years after orchiectomy. 69, 70, 73 As with other GU tract carcinoids, metastasis from another site must be entertained, especially in the presence of bilateral tumors. 74 Regarding primary lesions, early reports 69, 75, 76 postulated that analogous to carcinoids arising in ovarian teratomas, 77 primary testicular carcinoids may be derived from NE cells found in respiratory epithelial or enteric components of testicular teratomas. 69 However, a teratomatous component has been associated with only one-quarter of reported cases and intratubular germ cell neoplasia (ITGCN), a precursor lesion indicating germ cell origin, has generally been absent. 78 Although overgrowth of a single teratomatous component may be observed, the finding of a pure testicular carcinoid without other demonstrable germ cell tumor on initial sampling should engender extensive testicular sampling to discover ITGCN, a minute teratoma, and/or evidence of a scar, representing a ''burnt out''/regressed germ cell component (Fig. 4B) . 79 In the event of pure testicular carcinoid in association with OCT-4-labeling ITGCN, as recently reported, 80 cytogenetic studies to detect i12p may still be warranted, to eliminate the possibility of concurrent metastatic carcinoid. Once these efforts are exhausted, one may entertain other proposed origins, including origin from yet undiscovered NE rests 73 or designation of the lesion as a monodermal teratoma. 81 
NEUROENDOCRINE LESIONS OF PROSTATE Neuroendocrine Cells in the Prostate
First described in the prostate by Pretl 82 in 1944, focal NE cells are now known to be widely distributed in the prostate (Fig. 5A) , with greater abundance in major ducts than in acinar tissue. 83, 84 NE cells in prostate are members of the diffuse APUD cell system 85 and are thought to arise, along with prostatic secretory cells, from endodermal-derived pluripotent prostatic stem cells. 86, 87 Unlike luminal cells which have proliferative potential, some authors have considered these NE cells terminally differentiated. 86 Although their exact function is unknown, it is postulated that they are involved in both prostatic growth and differentiation, and also in homeostatic regulation of the secretory process. 88 Their role in these diverse processes may be mediated through their morphology, which includes both flask-shaped ''open'' cells with apical processes extending to the lumen and ''closed'' cells which interdigitate with normal secretory cells and contain long dendritic processes. 88 The existing literature on NE differentiation in prostate adenocarcinoma (PCa) reveals 3 major manifestations: (1) focal NE differentiation in PCa; (2) prostatic carcinoid tumor; (3) high-grade NE carcinoma.
Focal Neuroendocrine Differentiation in Prostate Cancer
Conventional PCa (30% to 100%) contain scattered NE cells, 48, 83, 89 most resembling other prostatic secretory cells on light microscopy. These cells may be detected immunohistochemically with markers such as chromogranin and/or bioactive hormones such as serotonin and somatostatin 90 and may express both PSA and PAP as well as NE markers. 91 Whether focal NE differentiation in prostatic adenocarcinoma has prognostic import is controversial, with a few studies suggesting correlation between increasing number of chromogranin-positive cells and worse prognosis. [92] [93] [94] [95] Conversely, most authors have correlated the extent of NE differentiation with increasing tumor grade and thus, have failed to show an independent effect on survival. 87, 90, [96] [97] [98] Likewise, there is evidence that metastatic PCa contains a population of NE cells, 99 which do not express the androgen receptor (AR) [100] [101] [102] and hence may not be suppressed by androgen ablation. 99 This had led to conjecture that NE cells possess the ability to ''escape'' usual hormonal therapy in advanced PCa, with some reports of increased NE differentiation in androgen-insensitive PCa and possible prognostic significance. 100, 103 However, others argue that these relationships depend on the agent used in androgen deprivation and have demonstrated no statistical correlation between amount of NE cells and diseasespecific survival. 97 These varying results suggest that the often limited and focal distribution of NE cells in PCa makes it difficult to study their relevance, especially in limited specimens, such as needle biopsies. 104 Nonetheless, a number of studies have shown potential roles for NE cells in PCa progression by paracrine growth stimulation of non-NE cells. 99, 103, 105 Occasionally, NE cells with bland nuclei and cytoplasmic eosinophilic granules, superficially resembling Paneth cells of the gastrointestinal tract, 106, 107 are seen in a patchy fashion in both normal and cancerous specimens (Figs. 5B, C) . These cells may correspond to the largetype ultrastructurally distinct granules described by di Sant'Agnese and de Mesy Jensen 108 and do not represent true Paneth cell metaplasia, as they stain with NE markers and do not contain lysozyme. Unusually, these cells may be observed as single cells, cords, or nests of tumor cells, meeting architectural criteria for Gleason pattern 5, yet displaying bland cytology and frequent association with lower grade conventional PCa. 107 A recent study found that among cases with Paneth cell-like rich areas resembling high-grade PCa, none showed evidence of progression. Cases exhibiting progression reflected typical parameters such as high Gleason scores and/or extraprostatic extension/seminal vesicle invasion. Diagnostically, it has been suggested that only the conventional carcinoma be graded in this scenario, as applying Gleason to such foci may inaccurately upgrade the tumor. 107 
Prostatic Carcinoid
The literature contains a fair number of cases denoted as ''prostatic carcinoid tumors.'' [109] [110] [111] [112] [113] [114] However, as usual PCa may exhibit at least focal NE differentiation, distinguishing carcinoidlike adenocarcinomas from a true primary prostatic carcinoid may be challenging. 109 Especially in Gleason grade 4/5 tumors, these entities may share nested and microacinar/''rosettelike'' patterns of growth with nuclear uniformity, PAP positivity, and immunohistochemical/ultrastructural evidence of NE differentiation. 115, 116 Furthermore, cellular aggregates with intensely eosinophilic NE granules, as described above, may also convey an impression of carcinoid tumor. 107 Most have argued, therefore, that tumors with expression of both PSA and NE markers, as well as cases of histologically mixed prostatic ''carcinoid'' and PCa are best considered carcinoidlike adenocarcinomas. 51, 117 This phenomenon may explain early reports of aggressive behavior for ''prostatic carcinoids,'' 118 likely reflecting high Gleason score tumors with varying degrees of focal NE differentiation. Using these guidelines, only a handful of tumors exhibiting typical carcinoid architecture and features, PSA negativity and absence of admixed adenocarcinoma have been described. 119, 120 Interestingly, an unusual case involving a 7-year-old boy with prostatic carcinoid unrelated to prostate cancer, in the setting of multiple NE neoplasia type IIb has also been documented. 121 High-grade Neuroendocrine Carcinoma
First described by Wenk et al 122 in 1977, prostatic SmCC represents between 1% and 5% of all prostatic malignancies when mixed adenocarcinoma-SmCC are included. 84 Moreover, data from a rapid autopsy program indicate that NE carcinomas evolve in only about 10% of PCa patients treated with hormonal therapy who develop androgen-insensitive disease. 123 Conversely, in the constellation of extrapulmonary SmCC, the prostate is a relatively common site. 124 The majority of prostatic SmCC lack clinically evident hormone production, with only rare reports of ectopic adrenocorticotropic or antidiuretic hormone secretion. 125 High-grade NEC of prostate histologically resembles the spectrum of SmCC/LCNEC described at other sites, [126] [127] [128] with approximately 1/2 of prostatic SmCC being composite tumors with conventional PCa. 84 Diagnostically, high-grade NEC should not be assigned a Gleason grade and may be differentiated from diffuse growth of Gleason pattern 5 PCa by the large cells with lower N/C ratio, prominent nucleoli, and absent nuclear molding seen in the latter (Fig. 5D ). 129 Conversely, due to its constellation of features, LCNEC may be easily mistaken for Gleason score 5+5 = 10 PCa and hence, the likelihood of its underdiagnosis is high. 126 A number of studies have reported the immunophenotype of SmCC and conventional PCa. 12, 130, 131 Overall, they have found strong labeling for PSA/PAP in most PCa, with at least focal expression in approximately 25% of SmCC, and diffuse NE marker labeling in SmCC with substantially less staining in usual PCa. 130, 131 Furthermore, although most have maintained that malignant NE cells do not express AR 100, 101 a recent study has demonstrated focal staining for AR in SmCC. 131 The presence of mixed prostatic acinar adenocarcinoma in many high-grade SmCC and LCNEC, coupled with evidence of cells that may coexpress PSA/PAP/AR and NE markers 126, 127, 130, 131 suggests evolution of a subset of multipotent non-NE prostatic tumor cells as the derivation for prostatic high-grade NEC. 86, 87, 126, 130, 132 As in high-grade NEC of the urothelium, local extension or distant spread of NEC from other sites must be excluded clinically, as morphologic and immunohistochemical features, including thyroid transcription factor-1 positivity, may be identical. 18, 131 Comparable to other sites, prostatic SmCC present at advanced stage, are often unresectable, and display a high frequency of visceral metastases and abysmal survival. 127, 133, 134 Small modern series have suggested managing prostatic SmCC with a combination of andro-gen deprivation and cisplatin-based therapies followed by consolidative surgery or radiotherapy. [133] [134] [135] However, as even chemotherapy-treated patients tend to progress rapidly, novel small molecule therapeutic approaches developed for pulmonary high-grade NEC, 136 have been considered for prostatic SmCC. To this end, Yao et al 131 have recently demonstrated high levels of labeling for CD56, bombesin/GRP, c-KIT, Bcl-2, and epidermal growth factor receptor in a small series of prostatic SmCC, suggesting future therapeutic targets.
Few examples of distinct prostatic LCNEC have been reported. 126, [137] [138] [139] Among these, the majority have been an incidental finding in palliative TURP of the prostate specimens in patients with androgen-independent disease. 126 As reported cases have been detected late in the disease course, widespread metastases to bone and viscera, uniformly poor responses to NE-specific chemotherapy and limited survival have been observed. 126 
